pSivida Announces 13 New Patents Issued or Allowed

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
pSivida Announces 13 New Patents Issued or Allowed

WATERTOWN, Mass., Aug. 29, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced the  addition of 13 U.S. and foreign issued patents and allowed applications since the start of 2016. This brings the total number of patents issued and applications allowed in the Company’s intellectual property portfolio to 42 in the U.S. and 191 in foreign jurisdictions. An additional 108 applications are pending in the U.S. and foreign jurisdictions.

Paul Ashton, Ph.D., president and CEO of pSivida, said, “Protection of our intellectual property continues to be extremely important to us. We have successfully secured intellectual property protection for our three FDA-approved products providing sustained drug delivery to the back of the eye and are working to build a solid patent foundation for future products.”

The 13 new patents issued and applications allowed include:

  • Two in the U.S. (both for Tethadur, pSivida’s large-molecule sustained-release delivery technology)
  • Eight in foreign jurisdictions (a total of five for Tethadur in Japan, China and Australia; one for the Medidur injector each in Japan and Hong Kong; and one for Medidur in Japan – Medidur is pSivida’s small molecule sustained release delivery technology)
  • Three design patents for the new smaller needle injector (two in Australia and one in Europe).

With these patents, pSivida’s intellectual property portfolio of issued patents and allowed applications consists of:

  • 10 U.S. and 82 foreign for Durasert;
  • 27 U.S. and 88 foreign for Tethadur;
  • 5 U.S. and 21 foreign for other pSivida technologies.

About pSivida Corp . pSivida Corp. ( www.psivida.com ), headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the U.S. and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida’s lead product candidate, Medidur™, a micro-insert for posterior segment uveitis being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in 2017. pSivida’s pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida please visit www.psivida.com  and connect on Twitter, LinkedIn, Facebook and Google+.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: Designation of Medidur as an orphan medicinal product; our ability to achieve profitable operations and access to capital; fluctuations in our operating results; further impairment of our intangible assets; declines in Retisert royalties; successful commercialization of, and receipt of revenues from, ILUVIEN for DME; the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of fluocinolone acetonide side effects; safety and efficacy results of the second Medidur Phase 3 trial, number of trials and data required for, and timing of filing and acceptance of, the Medidur NDA and EU marketing approval applications, if at all; ability to use data in a U.S. NDA from trials outside the U.S.; any exercise by Pfizer of its option with respect to the latanoprost product; our ability to develop Tethadur to successfully deliver large biologic molecules and develop products using it; our ability to successfully develop product candidates, initiate and complete clinical trials and receive regulatory approvals; our ability to market and sell products; the success of current and future license agreements; termination or breach of current license agreements; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements, even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Contact: Beverly Jedynak O: +1-312-943-1123 M: +1-773-350-5793  blj@bevlynconsulting.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 41

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 92

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 114

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 175

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Sunrise New Energy Unveils Innovative Solid-State Battery Patent

Updated Category News Views 205

Sunrise New Energy's Patent for Solid-State Battery Innovation Sunrise New Energy Co., Ltd. (NASDAQ: EPOW) has made significant strides in energy technology with the announcement of a groundbreaking invention patent for a novel method of creating lithium cerate-coated graphite iron oxide anode material. This development is a significant leap forward in the realm of...

Continue Reading
Leadership Transition at Lykos Therapeutics Following FDA Setback

Updated Category News Views 103

Leadership Change at Lykos Therapeutics After FDA Setback Amy Emerson has resigned as CEO of Lykos Therapeutics following significant regulatory hurdles. This change comes after the Food and Drug Administration (FDA) recently rejected the company's application for its ecstasy-based therapy aimed at treating post-traumatic stress disorder (PTSD). Consequences of FDA...

Continue Reading
RADCOM to Showcase Innovations at Upcoming Growth Conference

Updated Category News Views 228

RADCOM to Showcase Innovations at Growth Conference RADCOM Ltd. (Nasdaq: RDCM) is gearing up for a prominent appearance at the 28th Annual Needham Growth Conference. The conference will take place at the esteemed Lotte NY Palace Hotel, where the company is excited to highlight its cutting-edge technological advancements. Leadership Team Participation At this significant...

Continue Reading
Shoppers Prioritize Savings Over Convenience, Survey Reveals

Updated Category News Views 81

New Insights into Consumer Preferences During Holidays A recent survey conducted by GoDaddy sheds light on the evolving preferences of consumers as the holiday season approaches. The findings reveal that convenience often takes a backseat to cost savings, which fundamentally impacts how businesses engage with their customers. The Importance of Cost Savings According to...

Continue Reading
Criteo's Insider Trading Insights: What You Need to Know

Updated Category News Views 116

Understanding Recent Insider Trading at Criteo Recently, significant insider trading activity has caught the attention of investors and analysts. Notably, Ryan Damon, Chief Legal Officer at Criteo, made headlines with a prominent stock sale involving his holdings in the company. Insider Sales: A Breakdown During a recent filing, it was disclosed that Ryan Damon sold 3,393...

Continue Reading